Insilico continues to drive deep integration of cutting-edge AI technology with extensive scientific expertise, building a diversified internal pipeline covering over 40 innovative programs and 28 drug candidates at the IND-enabling stage, of which 12 have received IND clearance. The company operates a diversified business model spanning software licensing to leading pharma, out-licensing deals, and AI-enabled drug discovery collaborations, positioning it as a bridge between Big Pharma and AI-driven innovation in therapeutic development.
Cyborg Score Rationale
Insilico Medicine has been named to Fast Company's prestigious list of the World's Most Innovative Companies and the #3 Most Innovative Biotech Company of 2026. The company recently closed two megadeals (March 2026 Eli Lilly partnership valued at $2.75 billion and June 2026 SK Biopharmaceuticals partnership worth $2.5 billion) demonstrating market validation and commercial traction. Clinical proof-of-concept with rentosertib in Phase IIa trials validates its AI drug discovery model at scale.
Top Insights
In early 2026, Insilico achieved multi-billion dollar out-licensing momentum, with an Eli Lilly agreement signed in March 2026 valued at $2.75 billion, including an upfront payment of $115 million.
In June 2026, Insilico announced a record-breaking $2.5 billion global R&D collaboration with SK Biopharmaceuticals to develop central nervous system treatments, covering neuroimmune disorders.
In January 2026, Insilico partnered with Qilu Pharmaceutical Group on a drug development collaboration with near $120 million contract value for cardiometabolic disease therapies.
In April 2026, Insilico announced the formation of the industry's first Longevity Board, with Andrew Adams (Group Vice President of Molecular Discovery at Eli Lilly) as Chairman, signaling strategic focus on aging-related therapeutics.
Named Competitors
BenevolentAI — AI-powered drug discovery platform
Exscientia — AI-designed therapeutic compounds
DeepMind AlphaFold — Protein structure prediction for drug design
Lilly Drug Discovery — Large pharma partner with AI integration